ArticleCancer immunology, immunotherapy : CII2022
In vitro and in vivo evaluation of DC-targeting PLGA nanoparticles encapsulating heparanase CD4
Article in Cancer immunology, immunotherapy : CII, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Enhanced Transdermal Immunization via Solid-in-Oil Nanodispersions Incorporating Dendritic Cell-Targeting Peptide.Molecules (Basel, Switzerland) · 2026Article
- Targeting cytokine/chemokine signaling to convert immunologically cold tumors into hot: Emerging strategies in cancer immunotherapy.Acta pharmaceutica Sinica. B · 2026Review
- CD8+ Regulatory T Cells.Annual review of immunology · 2026Review
- Nanoparticles that modulate immune cells - an important strategy for the future treatment of tumors.Frontiers in immunology · 2026Review
- PLGA Nanoencapsulation Enhances Immunogenicity of Heat-Shocked Melanoma Tumor Cell Lysates.Cells · 2025Article
- Multi-epitope ligand-conjugated nanoparticles for tumor neoantigen targeting: advancing molecular precision in cancer immunotherapy.Medical oncology (Northwood, London, England) · 2025Review
- Forced intracellular degradation of xenoantigens as a modality for cell-based cancer immunotherapy.iScience · 2025Article
- PLGA-based nanoparticles in colorectal cancer immunotherapy: current concepts and future perspectives.Frontiers in pharmacology · 2025Review
- Cancer biotherapy: review and prospect.Clinical and experimental medicine · 2024Review
- Application of PLGA in Tumor Immunotherapy.Polymers · 2024Review
- PEG-Polymeric Nanocarriers Alleviate the Immunosuppressive Effects of Free 4-Thiazolidinone-Based Chemotherapeutics on T Lymphocyte Function and Cytokine Production.International journal of nanomedicine · 2024Article
- Nanomaterials in tumor immunotherapy: new strategies and challenges.Molecular cancer · 2023Review
- Cytokine Therapy Combined with Nanomaterials Participates in Cancer Immunotherapy.Pharmaceutics · 2022Review
- Cancer Immunotherapy and Delivery System: An Update.Pharmaceutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Heparanase has been identified as a universal tumor-associated antigen, but heparanase epitope peptides are difficult to recognize. Therefore, it is necessary to explore novel strategies to ensure efficient delivery to antigen-presenting cells. Here, we established a novel immunotherapy model targeting antigens to dendritic cell (DC) receptors using a combination of heparanase CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.